Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785323 | 0.93 | F10 (0.38) | MALT1F10ALDH1A1TLR9TLR8 | |
| SCHEMBL784125 | 0.90 | F10 (0.41) | NPY5RF10TLR9TLR8TLR7 | |
| SCHEMBL785210 | 0.89 | USP30 (0.44) | NPY5RMALT1F10ALDH1A1LMNA | |
| SCHEMBL785460 | 0.87 | TRPV1 (0.41) | NPY5RMALT1MCHR1F10ALDH1A1 | |
| SCHEMBL784619 | 0.86 | F10 (0.43) | NPY5RF10ALDH1A1TLR9TLR8 | |
| SCHEMBL785474 | 0.86 | NPC1 (0.46) | CYP2D6NPY5RF10ALDH1A1LMNA | |
| SCHEMBL785876 | 0.86 | F10 (0.41) | NPY5RF10TLR9TLR8TLR7 | |
| SCHEMBL785958 | 0.85 | F10 (0.38) | F10TLR9TLR8TLR7 | |
| SCHEMBL785369 | 0.84 | F10 (0.38) | NPY5RF10TLR9TLR8TLR7 | |
| SCHEMBL784621 | 0.84 | UBE2M (0.37) | CYP2D6F10ALDH1A1LMNATLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | CYP2D6 900/4885NPY5R 54/4885MALT1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.